Vaxcyte, Inc. (PCVX)

Vaxcyte Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-657.2	-463.93	-402.27	-223.49	-100.08	-89.22
Depreciation & Amortization	19.85	15.85	10.17	9.45	3.46	1.41
Loss (Gain) From Sale of Assets	-	-	-	-	0.1	0.03
Asset Writedown & Restructuring Costs	-	-	-	-	-	0.27
Loss (Gain) From Sale of Investments	-23.35	-38.7	-34.78	-0.95	1.41	-
Stock-Based Compensation	127.22	84.82	48.76	23.65	10.73	5.43
Other Operating Activities	-22.43	4.23	-	8	-	0.18
Change in Accounts Payable	29.55	34.58	11.23	2.9	-12.47	26.1
Change in Other Net Operating Assets	-15.78	-89.48	70.1	9.84	-24.54	9.17
Operating Cash Flow	-542.15	-452.63	-296.79	-170.6	-121.39	-46.63
Capital Expenditures	-78.58	-119.16	-67.88	-5.84	-6.56	-1.16
Sale of Property, Plant & Equipment	-	-	-	-	0.03	0.05
Investment in Securities	-156.36	-1,887	-705.43	80.43	-205.78	-
Investing Cash Flow	-234.94	-2,006	-773.31	74.59	-212.31	-1.11
Long-Term Debt Repaid	-	-	-	-	-	-0.06
Net Debt Issued (Repaid)	-	-	-	-	-	-0.06
Issuance of Common Stock	18.81	2,463	643.69	862.41	17.8	268.45
Other Financing Activities	-14.29	-14.29	-3.88	-0.86	-	-3.4
Financing Cash Flow	4.51	2,449	639.81	861.55	17.8	374.87
Foreign Exchange Rate Adjustments	3.61	0.43	-6.69	0.14	-0.44	0.09
Net Cash Flow	-768.96	-9.36	-436.97	765.67	-316.34	327.22
Free Cash Flow	-620.73	-571.79	-364.67	-176.44	-127.95	-47.78
Free Cash Flow Per Share	-4.57	-4.69	-3.75	-2.72	-2.46	-1.62
Cash Interest Paid	-	-	-	-	0.01	0.01
Levered Free Cash Flow	-381.07	-403.44	-202.41	-107.53	-88.16	-14.4
Unlevered Free Cash Flow	-381.07	-403.44	-202.41	-107.52	-88.16	-14.39
Change in Working Capital	13.77	-54.9	81.32	12.74	-37.01	35.27

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q